Prior Art Litigation Search in Brussels.

A prior art search Brussels litigation counsel can rely on has to fit an unusual venue map, because Brussels is the rare city that hosts two patent courts at once. Since 1 January 2015 the Brussels Enterprise Court has held exclusive national jurisdiction over every Belgian patent infringement and validity dispute, and the Brussels Local Division of the Unified Patent Court now sits in the same city. Add a dense pharma, biotech and chemicals base — UCB is headquartered here, and Belgium is one of Europe’s most patent-intensive life-science economies — and the local litigation theme is chemistry-heavy validity. PerspireIP builds invalidity-grade searches for the accused parties and counsel fighting those patents across Belgium, the EPO and the UPC.

Where a prior art search Brussels case is actually heard

Belgium concentrates all patent litigation in a single national forum. Since 1 January 2015, Article XI.337 of the Belgian Code of Economic Law has given the Brussels Enterprise Court (tribunal de l’entreprise de Bruxelles / ondernemingsrechtbank Brussel) exclusive national jurisdiction over patent infringement and validity, with appeals going to the Brussels Court of Appeal. A dispute rooted anywhere in Belgium — Antwerp chemicals, Ghent biotech, a Wallonia pharma process — is still filed and tried in Brussels. There is no other Belgian patent venue.

The legislator centralised patent cases in one court to raise the quality of the decisions. Because the Brussels court sits in both French-speaking and Dutch-speaking chambers, one early strategic choice is which language to litigate in. Whatever the language, the outcome of a Belgian nullity action turns on the same thing: what was publicly available before the priority date. The invalidity search is the engine of the case.

• Brussels Enterprise Court — exclusive first-instance court for Belgian infringement and nullity since 2015
• Brussels Court of Appeal — hears all Belgian patent appeals
• UPC Brussels Local Division — a second, parallel patent court in the same city
• EPO Opposition Division — central attack on a European patent within nine months of grant

Two patent courts in one city: the Brussels dual forum

Brussels is unusual because it houses two patent forums side by side. Alongside the national Brussels Enterprise Court, the city hosts the Brussels Local Division of the Unified Patent Court. Belgium ratified the UPC Agreement and was among the founding states when the court opened on 1 June 2023, so a European patent asserted here can be litigated either through the Belgian national route or through the UPC — and defendants need prior art ready for whichever forum the patentee picks.

The two courts do not overlap perfectly. The Brussels Enterprise Court invalidates the Belgian designation of a European patent (or a purely Belgian patent), while the UPC can revoke a unitary patent, or a non-opted-out European patent, across every participating state in one judgment. The Brussels Local Division is also distinctive in its languages: it is the only UPC local division that can run proceedings in four languages — Dutch, French, German and English — so the same case can be heard in the language that best suits the evidence.

For a defendant, the dual forum is a planning problem as much as a legal one. A patentee may sue at the UPC to reach the whole participating territory in one action, or stay national at the Brussels Enterprise Court to keep the fight to Belgium and away from a pan-European revocation. The choice affects timing, cost and the standard of proof on validity, but it does not change what beats the patent. The same body of prior art, charted against the same priority date, has to be ready before the patentee has picked its forum.

Belgian nullity, EPO opposition or UPC revocation: three routes

An accused party in Brussels usually has more than one way to attack a patent, and they are not interchangeable. A Belgian nullity action runs before the Brussels Enterprise Court and revokes the Belgian designation on grounds of lack of novelty, lack of inventive step, insufficiency or added matter. EPO opposition is a central attack: filed within nine months of grant, it can knock out the European patent in every designated state at once, decided on novelty and inventive step.

The Unified Patent Court adds a third route. A UPC revocation action can kill a unitary patent, or a European patent that has not been opted out, across all participating states in one judgment — and for Brussels defendants that action can be brought at the local division on their doorstep or before the UPC Central Division. Because many pharmaceutical patentees have kept their key European patents opted out of the UPC, the national Brussels Enterprise Court remains a live and important battleground alongside it.

The routes share one dependency: prior art. One rigorous invalidity search, charted claim by claim, can feed a Belgian nullity action, an EPO opposition and a UPC revocation at the same time, so the same evidence works across every forum.

UCB, pharma and chemicals: where Brussels patent fights come from

Brussels sits at the centre of one of Europe’s most patent-intensive life-science economies. UCB, the global biopharma with expertise in both chemistry and biologics, is headquartered in Brussels and manufactures at Braine-l’Alleud in Walloon Brabant just south of the city. Belgium as a whole is a per-capita pharma and biotech powerhouse, with clusters in Ghent, Leuven, Mechelen and Walloon Brabant feeding into the national forum in Brussels. Chemicals and logistics round out the industrial base.

Because every Belgian patent dispute is centralised in Brussels, the caseload is dominated by exactly this subject-matter: small molecules, formulations, biologics, peptides, gene therapy and chemical processes, plus the supplementary protection certificates that extend pharma exclusivity. Consumer-tech disputes are the exception. That concentration shapes how a defence has to be built — the decisive prior art for these claims is chemistry and life-science literature, not electronics art.

Where pharma, biotech and chemistry prior art lives

Chemistry and life-science patents are anticipated in a different literature than electronics or software. A great deal of the decisive art never appears in a patent database at all — it lives in the journal record and in specialist compound and sequence collections. A credible invalidity search in this field has to reach those sources and prove the public-availability date of each one.

• Chemical Abstracts (CAS) and the peer-reviewed journal literature, where a synthesis or compound may first be disclosed
• Sequence and structure databases for biologics, peptides and nucleic-acid claims
• Older patent families, often argued as inventive-step (obviousness) combinations under EPO problem-and-solution
• Conference abstracts, theses and dated technical disclosures that predate the priority date

For a formulation or process claim the anticipating reference is frequently an older paper or an abandoned patent family, not the headline blockbuster. We treat dating as evidence to be proved — establishing that each reference was genuinely public before the priority date the claim actually relies on, in the language a Brussels judge or a UPC panel expects to see.

Cross-border enforcement and the bilingual Belgian venue

Belgium is a small, open, cross-border market at the heart of Europe, so the same patent family is routinely asserted in Belgium, the Netherlands, Germany and France at once. A patent enforced before the Brussels Enterprise Court often has siblings enforced before the Dutch or German courts or at the UPC’s local divisions, and a defence built for Brussels should carry weight in those parallel proceedings too.

Language is the other Brussels-specific factor. The national court works in French or Dutch, and the UPC Brussels Local Division can run in Dutch, French, German or English. A prior art search Brussels counsel commissions therefore has to travel across languages — a reference that anticipates a claim in a Belgian nullity action should also stand up in an EPO opposition, a UPC revocation, or a parallel Dutch or German case. We build searches whose evidence and dating hold up whatever language the forum finally uses.

How PerspireIP builds a prior art search Brussels case can rely on

Every engagement follows the same disciplined path. We map the asserted claims element by element, fix the priority date that actually governs each one, and search against that date rather than the filing date on the cover. For pharma, biotech and chemistry subject-matter we run patent and deep non-patent-literature searching in parallel — CAS, journals, sequence and structure databases — then build claim charts a Brussels Enterprise Court judge, an EPO Opposition Division or a UPC panel can follow.

• Claim charting mapped to novelty and inventive step under the EPC and Belgian law
• Deep retrieval across CAS, peer-reviewed journals, sequence databases and older patent families
• Public-availability dating for every reference, evidenced in French, Dutch, German and English
• Prior art sized to your forum — a Belgian nullity action, the nine-month EPO opposition window, or UPC revocation
• A written invalidity analysis and reference packages ready for the Brussels courts, the EPO or the UPC

We work alongside your Belgian and European counsel as a specialist search partner, deliver to Brussels, EPO and UPC deadlines, and keep every engagement confidential. Whether you are a Belgian manufacturer facing an assertion, a generics or biosimilar entrant clearing a path, or litigation counsel preparing a cross-border defence, we scale to fit — a single search, a multi-patent campaign or ongoing support. Send us the patent number and your key dates, and we will scope a prior art search Brussels project within one business day.

IP Landscape & Resources in Brussels

Key intellectual-property authorities and venues relevant to Brussels:

• OPRI / FPS Economy (Belgian Office for Intellectual Property) — the Belgian patent office within the FPS Economy, which grants Belgian patents and administers national industrial-property rights
• Unified Patent Court (UPC) — hosts the Brussels Local Division and hears revocation of unitary and non-opted-out European patents across participating states
• European Patent Office (EPO) — grants European patents and runs post-grant opposition, a central attack filed within nine months of grant

Request a Prior Art Search in Brussels

Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.

Frequently Asked Questions